一线FOLFOXIRI联合贝伐珠单抗联合或不联合阿替利珠单抗治疗转移性结直肠癌患者(AtezoTRIBE):一项多中心、开放标签、随机、对照、2期试验
AtezoTRIBE研究在意大利22个肿瘤中心纳入218例既往未治疗的转移性结直肠癌患者,随机(1:2)分配至一线FOLFOXIRI联合贝伐珠单抗组(对照组)或联合阿替利珠单抗组。中位随访19.9个月,阿替利珠单抗组中位无进展生存期为13.1个月,对照组为11.5个月(HR 0.69,80% CI 0.56-0.85;p=0.012)。
要点
- 在既往未治疗的转移性结直肠癌患者中,一线FOLFOXIRI联合贝伐珠单抗基础上加用阿替利珠单抗安全,并改善无进展生存期。
- 阿替利珠单抗组中位无进展生存期13.1个月,对照组11.5个月,HR 0.69(80% CI 0.56-0.85;p=0.012)。
- 阿替利珠单抗组报告2例(1%)治疗相关死亡,对照组无报告。
核心结论
- 在既往未治疗的转移性结直肠癌患者中,一线FOLFOXIRI联合贝伐珠单抗基础上加用阿替利珠单抗安全,并改善无进展生存期。
研究设计与样本
- AtezoTRIBE是一项多中心、开放标签、随机、对照、2期研究,从意大利22个肿瘤中心招募患者。
- 纳入18-70岁ECOG体能状态0-2或71-75岁ECOG体能状态0、组织学确诊、不可切除、既往未治疗的转移性结直肠癌且器官功能足够的患者。
- 患者按中心、ECOG体能状态、原发肿瘤部位和既往辅助治疗分层,采用最小化算法随机(1:2)分配至对照组或阿替利珠单抗组。
- 对照组接受一线FOLFOXIRI(伊立替康165 mg/m2、奥沙利铂85 mg/m2、亚叶酸钙200 mg/m2、氟尿嘧啶3200 mg/m2 48小时输注,静脉给药)联合贝伐珠单抗(5 mg/kg静脉给药);阿替利珠单抗组接受相同方案联合阿替利珠单抗(840 mg静脉给药)。
- 联合治疗最多8个14天周期,随后根据随机分组接受氟尿嘧啶和亚叶酸钙联合贝伐珠单抗联合或不联合阿替利珠单抗维持治疗,直至疾病进展、不可接受的不良事件或撤回知情同意。
主要发现
- 2018年11月30日至2020年2月26日,218例患者被随机分配并接受治疗(对照组73例,阿替利珠单抗组145例)。
- 数据截止(2021年8月1日)时,中位随访19.9个月(IQR 17.3-23.9)。
- 阿替利珠单抗组中位无进展生存期为13.1个月(80% CI 12.5-13.8),对照组为11.5个月(80% CI 10.0-12.6);HR 0.69(80% CI 0.56-0.85;p=0.012);校正HR 0.70(80% CI 0.57-0.87);log-rank检验p=0.018。
- 最常见的全因3-4级不良事件为中性粒细胞减少(阿替利珠单抗组142例中59例[42%] vs 对照组72例中26例[36%])、腹泻(21例[15%] vs 9例[13%])和发热性中性粒细胞减少(14例[10%] vs 7例[10%])。
- 严重不良事件在阿替利珠单抗组39例(27%)和对照组19例(26%)中报告;阿替利珠单抗组报告2例(1%)治疗相关死亡(急性心肌梗死和支气管肺出血),对照组无报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune checkpoint inhibitors have not shown clinical benefit to patients with metastatic colorectal cancer who had proficient mismatch repair (pMMR) or microsatellite stable (MSS) tumours in previous studies. Both an active combination chemotherapy (FOLFOXIRI; fluorouracil, leucovorin, oxaliplatin, and irinotecan) and bevacizumab seem able to increase the immunogenicity of pMMR or MSS tumours. We aimed to provide preliminary evidence of benefit from the addition of the anti-PD-L1 agent atezolizumab to first-line FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer. METHODS: AtezoTRIBE was a multicentre, open-label, randomised, controlled, phase 2 study of patients (aged 18-70 years with an Eastern Cooperative Oncology Group [ECOG] performance status of 0-2 and aged 71-75 years with an ECOG performance status of 0) with histologically confirmed, unresectable, previously untreated metastatic colorectal cancer and adequate organ function, who were recruited from 22 oncology centres in Italy. Patients were stratified according to centre, ECOG performance status, primary tumour site, and previous adjuvant therapy. A randomisation system incorporating a minimisation algorithm randomly assigned (1:2) patients via a masked web-based allocation procedure to two groups: the control group received first-line FOLFOXIRI (intravenous 165 mg/m2 irinotecan, 85 mg/m2 oxaliplatin, 200 mg/m2 leucovorin, and 3200 mg/m2 fluorouracil as a 48 h infusion) plus bevacizumab (5 mg/kg intravenously), and the atezolizumab group received the same regimen plus atezolizumab (840 mg intravenously). Combination treatments were administered up to eight 14-day cycles followed by maintenance with fluorouracil and leucovorin plus bevacizumab with or without atezolizumab, according to randomisation group, until disease progression, unacceptable adverse events, or consent withdrawal. The primary endpoint was progression-free survival, analysed by the intention-to-treat principle. Safety was assessed in patients who received at least one dose of the study treatment. The study recruitment is completed. The trial is registered with Clinicaltrials.gov, NCT03721653. FINDINGS: Between Nov 30, 2018, and Feb 26, 2020, 218 patients were randomly assigned and received treatment (73 in the control group and 145 in the atezolizumab group). At the data cutoff (Aug 1, 2021), median follow-up was 19·9 months (IQR 17·3-23·9). Median progression-free survival was 13·1 months (80% CI 12·5-13·8) in the atezolizumab group and 11·5 months (10·0-12·6) in the control group (hazard ratio [HR] 0·69 [80% CI 0·56-0·85]; p=0·012; adjusted HR 0·70 [80% CI 0·57-0·87]; log-rank test p=0·018). The most frequent all-cause grade 3-4 adverse events were neutropenia (59 [42%] of 142 patients in the atezolizumab group vs 26 [36%] of 72 patients in the control group), diarrhoea (21 [15%] vs nine [13%]), and febrile neutropenia (14 [10%] vs seven [10%]). Serious adverse events were reported in 39 (27%) patients in the atezolizumab group and in 19 (26%) patients in the control group. Two (1%) treatment-related deaths (due to acute myocardial infarction and bronchopulmonary haemorrhage) were reported in the atezolizumab group; none were reported in the control group. INTERPRETATION: The addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab is safe and improved progression-free survival in patients with previously untreated metastatic colorectal cancer. FUNDING: GONO Foundation, ARCO Foundation, F Hoffmann-La Roche, and Roche.
引用
- Antoniotti C, Rossini D, Pietrantonio F, et al. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2022. PMID: 35636444. doi:10.1016/S1470-2045(22)00274-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。